Paul Rothman - Merck Director
| MRK Stock | MXN 2,176 56.07 2.65% |
Director
Dr. Paul B. Rothman is Independent Director of the Company. Dr. Rothman oversees the Johns Hopkins Health System and school of medicine. A rheumatologist and molecular immunologist, he joined Johns Hopkins in July 2012 after having served as dean of the Carver College of Medicine at the University of Iowa and leader of its clinical practice plan since 2008. He previously served as head of internal medicine at the University of Iowa from 2004 until 2008. Prior to that, he was vice chairman for research and founding director of the Division of Pulmonary, Allergy and Critical Care Medicine at Columbia University College of Physicians and Surgeons, where he joined the faculty in 1986. Dr. Rothman is a 1980 Phi Beta Kappa graduate of the Massachusetts Institute of Technology and earned his medical degree from Yale University in 1984. He is a member of the American Society for Clinical Investigation and is a fellow of the American College of Physicians. He was elected to the council of Association of American Physicians as a fellow of the American Association for the Advancement of Sciences and as a member of the American Clinical and Climatological Association. since 2015.
| Age | 60 |
| Tenure | 9 years |
| Phone | 908 740 4000 |
| Web | https://www.merck.com |
Merck Management Efficiency
The company has return on total asset (ROA) of 0.1268 % which means that it generated a profit of $0.1268 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.351 %, meaning that it generated $0.351 on every $100 dollars invested by stockholders. Merck's management efficiency ratios could be used to measure how well Merck manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Humberto Herrera | Grupo Sports World | 46 | |
| Enrique HernandezPulido | Grupo Sports World | N/A | |
| Cosme Martinez | Grupo Sports World | 56 | |
| Randy Rademacher | Air Transport Services | 61 | |
| Alfredo Torrado | Grupo Sports World | N/A | |
| John Teets | Air Transport Services | 45 | |
| Hadi Ibrahim | Grupo Sports World | 42 | |
| Robert Weissman | Cognizant Technology Solutions | 75 | |
| Zein Abdalla | Cognizant Technology Solutions | 59 | |
| Andrea Fossa | Grupo Sports World | N/A | |
| Xavier Berron | Grupo Sports World | N/A | |
| Cynthia Ayon | Grupo Sports World | 52 | |
| Robert Coretz | Air Transport Services | 54 | |
| Luis Platas | Grupo Sports World | N/A | |
| Omar Serio | Grupo Sports World | N/A | |
| Luis MacKissack | Grupo Sports World | 55 | |
| Maureen BreakironEvans | Cognizant Technology Solutions | 63 | |
| Fabian Castro | Grupo Sports World | N/A | |
| Hector Rivero | Grupo Sports World | N/A | |
| Carlos Elizondo | Grupo Sports World | 44 | |
| Jeffrey Vorholt | Air Transport Services | 65 | |
Management Performance
| Return On Equity | 0.35 | |||
| Return On Asset | 0.13 |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Glocer, Independent Director | ||
| Craig Thompson, Independent Director | ||
| Cristal Downing, Ex Officer | ||
| Jennifer Zachary, General Counsel | ||
| Rochelle Lazarus, Independent Director | ||
| Michael Rosenblatt, Executive Vice President Chief Medical Officer | ||
| Wendell Weeks, Independent Director | ||
| Michael Holston, Executive Vice President Chief Ethics and Compliance Officer | ||
| Paul Rothman, Director | ||
| Mary Coe, Director | ||
| Adele Ambrose, Senior Vice President Chief Communications Officer | ||
| Caroline Litchfield, Ex CFO | ||
| Joseph Romanelli, IR Contact Officer | ||
| Mirian GraddickWeir, Executive Vice President - Human Resources | ||
| Peter Wendell, Independent Director | ||
| John Noseworthy, Independent Director | ||
| Jennifer Mauer, VP Communications | ||
| Leslie Brun, Independent Director | ||
| Julie Gerberding, Executive Vice President - Strategic Communications, Global Public Policy & Population Health | ||
| Inge Thulin, Director | ||
| Pamela Craig, Director | ||
| Patricia Russo, Independent Director | ||
| David Williams, Ex Officer | ||
| Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division | ||
| Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller | ||
| Lisa LeCointeCephas, VP Officer | ||
| Robert Davis, CFO and Executive VP | ||
| Robert Kidder, Independent Director | ||
| Thomas Cech, Independent Director | ||
| Michael Nally, Chief Marketing Officer | ||
| Peter Dannenbaum, VP Relations | ||
| Clark Golestani, Executive Vice President CIO | ||
| William Harrison, Lead Independent Director | ||
| Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
| Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer | ||
| Steven Mizell, Chief Human Resource Officer | ||
| Jim Scholefield, Chief Information and Digital Officer | ||
| Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
| Adam Schechter, President of Global Human Health and Executive VP | ||
| Carlos Represas, Independent Director | ||
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
| Kenneth Frazier, Chairman, CEO and Pres | ||
| Frank Clyburn, Chief Commercial Officer | ||
| Robert JD, Pres Chairman |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.35 | |||
| Return On Asset | 0.13 | |||
| Profit Margin | 0.24 % | |||
| Operating Margin | 0.38 % | |||
| Current Valuation | 5.9 T | |||
| Shares Outstanding | 2.54 B | |||
| Shares Owned By Insiders | 0.10 % | |||
| Shares Owned By Institutions | 76.37 % | |||
| Price To Earning | 469.71 X | |||
| Price To Book | 6.28 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Merck in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Merck's short interest history, or implied volatility extrapolated from Merck options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Merck Stock analysis
When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |